NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Intellia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.58+0.16 (+1.40%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Intellia Therapeutics has not reported a dividend
No dividend per share appears in Intellia Therapeutics's annual filings since fiscal 2014.